Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegilodecakin + Nivolumab in 2nd-line NSCLC (Cypress 2)
NCT03382912Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Primary completion
- Aug 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of ilodecakin in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Mar 2018; status: terminated.
02
Drugs
ilodecakin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03382912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382912.